247582-62-3

Basic information

• Product Name: 6-AMINO-5-BROMOPYRIDINE-3-SULFONIC ACID
• Synonyms: IFLAB-BB F1371-0173;AURORA 23194;6-AMINO-5-BROMOPYRIDINE-3-SULFONIC ACID;6-AMINO-5-BROMOPYRIDINE-3-SULPHONIC ACID;6-AMINO-5-BROMO-3-PYRIDINE SULFONIC ACID;AKOS BBS-00001321;2-AMINO-3-BROMOPYRIDINE-5-SULFONIC ACID;PYRIDIN-2-AMINO-3-BROMO-5-SULFONIC ACID
• CAS NO: 247582-62-3
• Molecular Formula: C5H5BrN2O3S
• Molecular Weight: 253.07
• Product Categories: Aromatics Compounds;Aromatics;Bases & Related Reagents;Nucleotides;Sulfur & Selenium Compounds;Pyridines
• Mol File: 247582-62-3.mol

Chemical Properties

• Melting Point: >250°C
• Appearance: /
• Density: 2.042 g/cm³
• Refractive Index: 1.669
• Storage Temp.: Refrigerator
• Solubility: Sparingly soluble in DMSO and Water
• PKA: -1.98±0.50(Predicted)
• CAS DataBase Reference: 6-AMINO-5-BROMOPYRIDINE-3-SULFONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 6-AMINO-5-BROMOPYRIDINE-3-SULFONIC ACID(247582-62-3)
• EPA Substance Registry System: 6-AMINO-5-BROMOPYRIDINE-3-SULFONIC ACID(247582-62-3)

Safety Data

• HazardClass: 8
• Hazardous Substances Data: 247582-62-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C5H5BrN2O3S/c6-4-1-3(12(9,10)11)2-8-5(4)7/h1-2H,(H2,7,8)(H,9,10,11)

Upstream product

• 16250-08-1 pyridine-2-amino-5-sulphonic acid 
• 504-29-0 2-aminopyridine 

Downstream Products

• 216394-05-7 5-bromo-6-chloropyridine-3-sulfonyl chloride 
• 247582-73-6 2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic Acid 

Relevant articles and documents

The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics

This paper describes our recent efforts to design and synthesise potent and selective PDE5 inhibitors and the use of in vitro predictors of clearance, absorption and permeability to maximise the potential for dose-proportional pharmacokinetics and good oral bioavailability in man. Optimisation of the preclinical profile resulted in the identification of UK-369003 (19a) and its nomination as a clinical candidate. The clinical pharmacokinetic and safety profile has enabled us to progress the compound to test its efficacy in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and a paper describing its efficacy has recently been published.2,3.

Treatment of neuropathy

This invention relates to the use of cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of neuropathy, including in particular the treatment of diabetic neuropathy.

Treatment of diabetic ulcers

This invention relates to the use of cyclic guanosine 3′, 5′-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of diabetic ulcers, particularly diabetic foot ulcers.

Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction

The present invention provides a method of treating female sexual dysfunction, the method comprising the step of administering to a patent, having or at risk of having one or more of the disorders or conditions associated with female sexual dysfunction, a therapeutically effective amount of a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of alpha-melanocyte stimulating hormone to melanocortin receptors. The present invention also provides a method of identifying a compound that is useful for the treatment or prevention of female sexual dysfunction, the method comprising the steps of: 1) determining if a compound affects the binding of agouti-related protein to melanocortin receptors; 2) determining if a compound affects the binding of alpha-melanocyte stimulating hormone to melanocortin receptors; and 3) selecting a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not affect the binding of alpha-melanocyte stimulating hormone to melanocortin receptors.

Methods of treatment and kits comprising a growth hormone secretagogue

The present invention relates to methods of treating bulimia nervosa, male erectile dysfunction, female sexual dysfunction, thyroid cancer, breast cancer, or ameliorating ischemic nerve or muscle damage. The present invention also relates to kits that can be used in the treatment of bulimia nervosa, male erectile dysfunction, female sexual dysfunction, thyroid cancer, breast cancer, or ameliorating ischemic nerve or muscle damage. The present invention further relates to increasing gastrointestinal motility after surgery and increasing gastrointestinal motility in patients who have been administered an agent that decreases gastrointestinal motility.

Novel process for the preparation of pyrazolopyrimidinones

There is provided a process for the production a compound of general formula I: 1wherein A, R1, R2, R3 and R4 have meanings given in the description, which process comprises the dehydrogenation of a compound of general formula II, 2

Novel process for the preparation of pyrazolopyrimidinones

There is provided a process for the production a compound of general formula I: wherein A, R1, R2, R3 and R4 have meanings given in the description, which process comprises the reaction of a compound of formula II, wherein Rx is a group substitutable by an aminopyrazole, with a compound of general formula III

Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction

There is provided compounds of formula IA and of formula IB, wherein R1, R2, R3, R4and A have meanings given in the description, which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.

Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction

Compounds of the formulae (IA) and (IB): wherein R1is C1to C3alkyl optionally substituted with phenyl, Het or a N-linked heterocyclic group selected from piperidinyl and morpholinyl; wherein said phenyl group is optionally substituted by one or more substitutents selected from C1to C4alkoxy; halo; CN; CF3; OCF3or C1to C4alkyl wherein said C1to C4alkyl group is optionally substituted by C1to C4haloalkyl or haloalkoxy either of which is substituted by one or more halo atoms; R2is C1to C6alkyl and R13is OR3or NR5R6, or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity are potent and selective inhibitors of type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).

Compositions and methods of treatment for conditions responsive to testosterone elevation

This invention relates to methods and pharmaceutical compositions useful in the treatment of conditions that are responsive to the elevation of testosterone levels in the body and the use of estrogen agonists/antagonists for the manufacture of medicaments for the treatment of conditions that are responsive to the elevation of testosterone levels in the body. The compositions are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier or diluent. These compositions are effective in treating male subject sexual dysfunction and timidity in female subjects including post-menopausal women and are effective in increasing libido in female subjects including post-menopausal women. In the case of male subject sexual dysfunction, the compositions may also include a compound which is an elevator of cyclic guanosine 3′,5′-monophosphate (cGMP). Additionally, the compositions are effective in other conditions whose etiology is a result of testosterone deficiency or which can be ameliorated by increasing testosterone levels within the body. Methods of the invention include the treatment of conditions that are responsive to elevation of testosterone levels such as treating male subject sexual dysfunction and timidity in female subjects including post-menopausal women and the increase of libido of female subjects including post-menopausal women. The methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with testosterone administration.